The transition from academic research to commercial MedTech entrepreneurship requires a strategic mindset shift, particularly when navigating high-risk vascular innovations. Jordi Martorell, CEO and co-founder of Aortyx, shares his journey from mapping arterial blood flow at the Harvard-MIT Biomedical Engineering Center to developing bioresorbable endovascular patches for aortic dissection. Driven by a desire to solve true unmet medical needs, Martorell leveraged his background in fluid mechanics and vascular engineering to build a company capable of transforming clinical outcomes.
Navigating early-stage funding outside major venture capital hubs presents unique structural challenges. Martorell explains how Aortyx sustained a multi-year development timeline prior to Series A by combining friends-and-family rounds, community equity crowdfunding, and non-dilutive European public grants. Maintaining radical transparency regarding investment risk and establishing clean cap table structures were critical components in maintaining investor trust over extended timelines.
Securing a Series A round for a Class III medical device requires managing shifting macroeconomic landscapes, rising clinical costs, and complex regulatory pathways. Martorell reflects on the realities of negotiating with venture capital firms, facing unexpected round restructurings, and adapting to post-pandemic inflation across preclinical and clinical trial execution. The discussion highlights the importance of maintaining core product continuity while remaining flexible in execution strategy.
Takeaways
- Validate Unmet Needs Over Market Incrementalism: Avoid competing in saturated markets where large strategics only seek non-inferiority; focus R&D on clear, unaddressed clinical gaps.
- Structure Clean Cap Tables for Retail Capital: When utilizing equity crowdfunding or large groups of early individual investors, leverage syndication and SPVs to preserve a single point of negotiation for future institutional VCs.
- Prepare for Extended Series A Timelines: Deep-tech Class III devices can face multi-year fundraising cycles, requiring a multi-tiered capital strategy blending non-dilutive grants, bridge rounds, and follow-on commitments.
- Factor Post-Pandemic Inflation into Preclinical Budgets: Account for significant cost increases in animal studies, raw material procurement, and clinical trial execution compared to historical baseline estimates.
References
- Aortyx: Medical device company developing bioresorbable endovascular patches for aortic dissection repair.
- EIC Accelerator Program: European Innovation Council grant initiative providing non-dilutive funding to high-impact European startups.
- Capital Cell: Specialized health-focused equity crowdfunding platform based in Spain.
- Etienne Nichols: LinkedIn Profile
Feedback Call-to-Action
We want to hear from you. What were your key takeaways from this episode? Do you have topics or guest suggestions for future discussions? Send your thoughts, feedback, and questions directly to [email protected]. Every email is reviewed by our team to help shape upcoming episodes.
Sponsors
This episode is brought to you by Greenlight Guru.
Learn how Greenlight Guru's modern QMS and EDC software can support your medical device journey at greenlight.guru.
Global Medical Device Podcast powered by Greenlight Guru